⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NXTS News
Nexentis Technologies Inc. Common Stock
Form 8-K
sec.gov
NXTS
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
globenewswire.com
NXTS
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
globenewswire.com
NXTS
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
globenewswire.com
NXTS
Form 8-K
sec.gov
NXTS
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
globenewswire.com
NXTS
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
globenewswire.com
NXTS
Form 8-K
sec.gov
NXTS
Form 8-K
sec.gov
NXTS
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
globenewswire.com
NXTS